Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy

The aim of this study was to evaluate if bone marrow (BM) SUVmax measured on pre-treatment 18F-FDG PET/CT predicts the clinical outcome of locally advanced cervical cancer (LACC). We recruited retrospectively patients with LACC who underwent staging 18F-FDG PET/CT and had baseline blood tests, then...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Seban, Romain-David, Robert, Charlotte, Dercle, Laurent, Yeh, Randy, Dunant, Ariane, Reuze, Sylvain, Schernberg, Antoine, Sun, Roger, Mignot, Fabien, Terroir, Marie, Schlumberger, Martin, Haie-Meder, Christine, Chargari, Cyrus, Deutsch, Eric
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2019
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492982/
https://ncbi.nlm.nih.gov/pubmed/31069132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1574197
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares